Disclosed herein are uses of 4210 peptide as a marker in the diagnosis of liver cancer and cirrhosis. The 4210 Da peptide is differentially expressed in the serum samples of subjects with different hepatitis B-associated liver diseases, specifically, the expression level is the highest in patients with chronic hepatitis B, sequentially followed by patients with cirrhosis and hepatocellular carcinoma, and healthy controls and those with natural clearance of hepatitis B virus have the lowest expression level of the 4210 Da peptide. The invention provides a novel marker for assisting the diagnosis of a hepatitis B-associated liver disease, which can effectively assist the diagnosis of the hepatocellular carcinoma and the cirrhosis developed from chronic hepatitis B, benefiting the early diagnosis of hepatitis B-associated liver diseases.

Disclosed are biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of one or more of ST2, ANG2, L-Ficolin, HA, and VCAM1 for prognosing, diagnosing, and/or treating SOS.

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

The invention relates to a method for the diagnosis of non-alcoholic steatohepatitis (NASH), for determining the activity, the stage, or the severity of NASH or for classifying a subject as a potential receiver or non receiver of a treatment of NASH using circulating miRNAs and other blood circulating markers of liver damage, e.g. alpha 2 macroglobulin, HbA1c, N-terminal pro-peptide of collagen type III, miR-34 and miR-200. It also relates to a kit for implementing the method of the invention, and the compounds for use in a method for the treatment of NASH, wherein the subject to be treated is identified, evaluated or classified according to the method of the invention.

Disclosed are methods and articles (e.g., gene arrays or antibodies) for determining the progression or regression of liver fibrosis, for the diagnosis of liver disease, and for screening compounds for hepatotoxicity and efficacy against liver fibrosis. Related therapeutic methods also are disclosed.

Provided is a method of detecting a biological material, by which quantitative measurement can be performed easily. The method of detecting a biological material in a sample includes: mixing, with the sample, a fusion protein (C) in which a protein (A) capable of binding the biological material and a chemiluminescent protein (B) are fused together and a substrate for the chemiluminescent protein (B); and observing a luminescent signal from the sample, wherein the protein (A) and the protein (B) are linked in such a manner that resonance energy transfer can occur, the protein (A) is either a protein (A1) that can emit fluorescence in a state where the biological material is bound thereto or a protein (A2) capable of binding an autofluorescent molecule as the biological material, and the protein (B) can excite fluorescence or autofluorescence of the protein (A) with its luminescence energy.

The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD. Also provided herein are methods for treating ALD.

The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.

An ex vivo method for the diagnostic and/or prognostic assessment of the acute-on-chronic liver failure (ACLF) syndrome in a patient with a liver disorder, includes measuring a panel of metabolites related with acylcarnitines-sialic acid-acetylated amino acids and amino acid derivatives and/or sugar alcohols, catecholamines and pyrimidine derivatives in a biological sample of the patient, and comparing the level of the metabolites in the sample with the level of the metabolites in healthy patients. An increase of at least 1.2 times of the level of the metabolites is indicative of ACLF syndrome.

An object of the present invention is to provide human fatty-liver model cells showing symptoms of the hepatic tissue of fatty liver. The present invention relates to human fatty-liver model cells, which are produced by culturing human hepatocytes derived from fatty liver in a medium containing dimethyl sulfoxide.